ArticlePloS one2025
Magnetic resonance evaluation of three-dimensional liver fat fraction by hepatitis C status and associations with inflammatory cytokines.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
backgroundChronic hepatitis C virus (HCV) infection may influence cytokine and insulin-like growth factor (IGF-1) levels, which could contribute to increased hepatic steatosis. We utilized MRI to compare three-dimensional volumetric liver fat fraction by chronic HCV status and evaluated associations between liver fat fraction and inflammatory cytokines and IGF-1.
methodsParticipants with untreated, non-genotype 3 chronic HCV and participants without HCV were enrolled between 2019-2022 and underwent MRI to quantify three-dimensional volumetric liver fat fraction. Interleukin (IL)-6, IL-18, tumor necrosis factor (TNF)-α, and IGF-1 were also measured. Multivariable linear regression was used to determine associations between liver fat fraction, chronic HCV, and cytokine and IGF-1 levels.
resultsAmong 54 participants with HCV and 54 without HCV, median volumetric liver fat fraction was 12.4% (IQR: 9.3, 18.0%) and 10.9% (IQR: 8.7, 13.3%), respectively. After adjustment for age, sex, and body mass index, mean liver fat fraction was 2.28% (95% CI: 0.55, 4.02%) higher in participants with HCV. HCV was associated with higher mean log TNF-α (0.11 [95% CI: 0.06, 0.16]) and IL-18 (0.14 [95% CI: 0.05, 0.24]), but lower mean log IGF-1 (-0.18 [95% CI: -0.26, -0.11]) when compared to those without HCV. IL-6, IL-18, TNF-α, and IGF-1 were not associated with liver fat fraction.
conclusionChronic HCV is associated with higher volumetric liver fat fraction by MRI. TNF-α and IL-18 levels were higher with chronic HCV but were not associated with liver fat fraction. Further research is needed to identify alternative mechanisms that potentiate liver fat deposition in chronic HCV.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.